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Background: IL28B and ITPA genetic variants are associated with the outcome of pegylated-interferon and ribavirin
(PEG-IFN/RBV) therapy. However, the significance of these genetic variants in cirrhotic patients following
splenectomy has not been determined.
Methods: Thirty-seven patients with HCV-induced cirrhosis who underwent laparoscopic splenectomy (Spx group)
and 90 who did not (non-Spx group) were genotyped for IL28B and ITPA. The outcome or adverse effects were
compared in each group. Interferon-stimulated gene 15 (ISG15) and protein kinase R expression in the spleen was
measured using total RNA extracted from exenterate spleen.
Results: Sustained virological response (SVR) rate was higher in patients carrying IL28B major genotype following
splenectomy (50% vs 27.3%) and in patients carrying minor genotype in the Spx group compared to non-Spx
group (27.3% vs 3.6%, P < 0.05). Pretreatment splenic ISG expression was higher in patients carrying IL28B major.
There was no difference in progression of anemia or thrombocytopenia between patients carrying each ITPA
genotype in the Spx group. Although splenectomy did not increase hemoglobin (Hb) level, Hb decline tended to
be greater in the non-Spx group. In contrast, splenectomy significantly increased platelet count (61.1 × 103/μl vs
168.7 × 103/μl, P < 0.01), which was maintained during the course of PEG-IFN/RBV therapy.
Conclusions: IL28B genetic variants correlated with response to PEG-IFN/RBV following splenectomy. Splenectomy
improved SVR rate among patients carrying IL28B minor genotype and protected against anemia and
thrombocytopenia during the course of PEG-IFN/RBV therapy regardless of ITPA genotype.
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Hepatitis C virus (HCV) chronically infects over 170
million people worldwide, with 3–4 million individuals
newly infected each year. Liver cirrhosis may progress in
30% of chronic hepatitis C patients, and even hepatocel-
lular carcinomas develop in 7–8% of cirrhotic patients
annually [1,2]. Although the current standard therapy
for HCV is combination of pegylated-interferon plus
ribavirin (PEG-IFN/RBV), sustained virological response
(SVR), defined as negativity for HCV RNA for 24 weeks
after cessation of therapy, can be achieved for only 50%* Correspondence: kshirabe@surg2.med.kyushu-u.ac.jp
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distribution, and reproduction in any mediumof chronic hepatitis patients, and for <30% of cirrhotic
patients [3,4]. In addition to low efficacy, many adverse
effects, especially cytopenia, are extremely detrimental
to cirrhotic patients.
Splenectomy is recommended for cirrhotic patients
with thrombocytopenia to enable them to receive PEG-
IFN/RBV therapy safely [5]. Although patients with liver
cirrhosis have a high risk of hemorrhage due to dilated
collateral vessels, splenomegaly, and poor liver function,
we have demonstrated the safety and feasibility of lap-
aroscopic splenectomy (LS) since its first report in 1992
[6,7]. In particular, it could be very effective for cirrhotic
patients who have failed induction of PEG-IFN/RBV
therapy due to low platelet counts [8].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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revealed two striking single nucleotide polymorphisms
(SNPs), IL28B and ITPA, which are correlated with
the outcome or adverse effects of PEG-IFN/RBV ther-
apy [9-11]. A lower VR rate has been shown in
patients carrying the minor genotype (TG or GG) at
rs8099917 near the IL28B locus, and treatment-
induced hemolytic anemia has been reported more
often in patients carrying the major genotype (CC) at
rs1127354 in the ITPA gene. In addition, ITPA genetic
variants have also been reported recently to correlate
with platelet reduction during PEG-IFN/RBV therapy
[12].
However, the significance of these two SNPs among
patients who have undergone LS has yet to be deter-
mined. For more than a little patients could not
achieved virological response or would failed the inces-
sancy of PEG-IFN/RBV even after splenectomy, it
would be very beneficial to predict the outcomes of
anti-HCV therapy following splenectomy. In the current
study, we demonstrated the association of IL28B and




From August 2004 to March 2009, 117 consecutive type
C cirrhotic patients underwent LS at our institute for
the induction of PEG-IFN/RBV therapy, and DNA was
available for genotyping from 37 of these. They were
compared to 90 cirrhotic patients who did not undergo
splenectomy before induction of PEG-IFN/RBV therapy
in the same period at the Department of General In-
ternal Medicine, Kyushu University. Patients in the con-
trol group were selected on account of their platelet
count <105/ml or by METAVIR fibrosis stage F4 [13].
Therefore, 127 patients were enrolled in the current
study, which was approved by the Ethics Committee of
Kyushu University.
DNA extraction and genotyping
Genomic DNA was extracted from the patients’ spleen
tissues obtained at operation, or from peripheral blood
mononuclear cells in the control group. IL28B genetic
polymorphism (rs8099917) and ITPA genetic poly-
morphism (rs1127354) were genotyped using StepOne-
PlusTM real-time PCR system (Applied Biosystems,
Carlsbad, CA, USA).
Definition of outcomes of PEG-IFN/RBV therapy
VR was defined as a lack of HCV RNA in response to
the treatment regimen, regardless of whether a relapse
occurred when treatment was terminated. SVR wasdefined as undetectable HCV-RNA 24 weeks after the
end of the therapy. Patients who had achieved VR but
had showed relapse were defined as end of treatment
response (ETR)-relapse. Hemoglobin (Hb) level or
platelet count was assessed before splenectomy, at in-
duction of therapy, and every 4 weeks during the
course of PEG-IFN/RBV therapy.
RNA extraction and reverse transcriptase polymerase
chain reaction (RT-PCR)
Total RNA was extracted from exenterate spleen speci-
mens using ISOGEN (Nippon Gene, Tokyo, Japan) and
reverse transcription was performed using SuperScriptIII
(Invitrogen, Carlsbad, CA, USA). Quantitative PCR was
performed using SYBRW Green assay (Applied Biosys-
tems) on the LightCyclerW480 Real-Time PCR system
(Roche Applied Sciences, Indianapolis, IN, USA). Spe-
cific primers for ISG15 were as follows: 50-agcgaa
ctcatctttg-30 for sense primer 50-cagctctgacaccgacatgga-30
for antisense primer. Specific primers for protein kinase
R (PKR) were 50-acgtgtgagtcccaaagcaac-30 for sense
and 50-ctgagaccattcataagcaacg-30 for antisense. β-Actin
expression was used for endogenous control with
50-ct ggcaccacac cttctacaatg-30 for sense primer and
50-ggcgtacagggatagcacagc-30 for antisense primer.
Statistical analysis
All data were analyzed using JMPW statistical software
(SAS Institute, Cary, NC, USA). A χ2 test was performed
for qualitative variables and a Wilcoxon test was per-
formed for quantitative variables.
Results
Patients’ characteristics
Characteristics of patients who underwent splenectomy
(Spx) and those who did not (non-Spx) are shown in
Table 1. Although patients in the non-Spx group were
selected on account of their platelet count <105/μl,
count before surgery in the Spx group was lower than
that in the non-Spx group (6.1 × 104/μl vs 8.7 × 104/μl,
respectively, P < 0.0001), as well as their Hb level (12.5
g/dl vs 13.2 g/dl, respectively, P = 0.03). Both alanine
aminotransferase and γ-glutamyl transpeptidase levels
were significantly higher in the non-Spx group (55 IU/l
vs 91 IU/l, P = .001, 45 IU/l vs 60 IU/l, P = 0.02, respect-
ively), but albumin level was higher in the non-Spx
group (3.3 mg/dl vs 3.9 mg/dl, P < 0.0001). The progres-
sion of cirrhosis was considered to be more severe in the
Spx group. Neither pretreatment viral load nor the fre-
quency of HCV genotype differed among these groups.
The allele frequency of both IL28B (rs8099917) and
ITPA (rs1127354) genetic polymorphisms was similar in
these groups.
Table 1 Data Among HCV-positive patients who underwent splenectomy (Spx group) and who did not (non-Spx group)
Spx group (n=37) Non-Spx group (n=90) P value
Age (y), mean ± SD 58 ±1 61 ± 1 n.s
Sex (male / female), n 19 / 18 44 / 46 n.s
Body Mass Index (kg/m2), mean ± SD 24.9 ± 0.5 22.7 ± 0.5 0.002
Hemoglobin level (g/dl), mean ± SD 12.5 ± 0.3 13.2 ± 0.2 0.03
Platelet count (x104/μl), mean ± SD 5.9 ± 0.2 8.7 ± 0.2 <0.0001
Alanine aminotransferase level (IU/L), mean ± SD 55 ± 10 91 ± 7.9 0.001
Gamma-glutamyle transpeptidase (IU/L), mean ± SD 45 ± 7.4 60 ± 5.1 0.02
Albumin level (g/dl), mean ± SD 3.3 ± 0.07 3.9 ± 0.06 <0.0001
Pretreatment viral load (logIU/mL), mean ± SD 5.9 ± 0.1 6.2 ± 0.1 n.s
HCV genotype (1/2), n 32 / 5 69 / 21 n.s
IL28B genotype (major/minor), n 26 / 11 62 / 28 n.s
ITPA genotype (major/minor), n 26 / 11 61 / 29 n.s
HCV; hepatitis C virus, IL28B; interleukin-28B, ITPA; inosine triphosphate pyrophosphatase, n.s ; not significant.
Spx; splenectomy.
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following splenectomy
Fifty-four of 127 patients achieved a SVR (42.5%).
Patients carrying IL28B the major genotype (TT allele at
rs8099917, n = 88) showed a significantly higher SVRFigure 1 IL28B genetic polymorphism and response to PEG-IFN/RBV (
represents the rate in percentile). (A) IL28B genetic polymorphism and resp
rate between Spx and non-Spx groups. (C) IL28B genetic polymorphism anrate compared to those carrying the minor genotype
(TG or GG, n = 39) (56.8% vs 10.3%, P < 0.0001,
Figure 1A). To clarify the effect of splenectomy on the
outcome of PEG-IFN/RBV therapy, SVR rate was com-
pared between the Spx and non-Spx groups. Althoughblack bar: SVR, grey bar: ETR-relapse, white bar: NR). Each number
onse rate among patients with HCV-induced cirrhosis. (B) Response
d each response rate in the Spx and non-Spx groups.
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than in the non-Spx group (27.0% vs 18.9%), there was
no significant difference in SVR rate between the two
groups (43.2% vs 42.3%, P =0.91, Figure 1B).
SVR rate among each IL28B genotype in the Spx
and non-Spx groups was compared. As shown in
Figure 1C, IL28B genetic variants were significantly
associated with SVR rate in the non-Spx group (58.9%
vs 4.1%, P < 0.0001). SVR rate in the Spx group was
not different between IL28B genotype (50% vs 27.3%,
P=0.09), probably because of small number, but VR
rate (SVR + ETR-relapse) of Spx group was higher in
IL28B major group compared to those in minor group
(80.8% vs 45.5%, P <0 .05). Interestingly, patients carry-
ing the minor genotype in the Spx group showed a sig-
nificantly higher SVR rate than those in the non-Spx
group (27.3% vs 3.6%, P < 0.05), whereas there was no
difference in SVR rate among patients carrying the
major genotype between the SPx and non-Spx groups
(50.0% vs 59.7%, P = 0.40).
It is well-known that IFN response is correlated with
HCV genotype. Therefore, we made the same analysis
on 100 patients infected with only genotype 1 HCV. The
similar results were obtained, but no statistical difference
in SVR rate among IL28B minor allele carriers between
Spx- and non-Spx-group, probably because of small
number (20.0% vs 3.7%, data not shown).
Next, we checked the prognostic factors for achieving
SVR among IL28B minor allele carriers. As shown in
Table 2, splenectomy was the only significant factors for
SVR with odds ratio of 10.1 (p<0.05).ITPA genotype and PEG-IFN/RBV-induced anemia
following splenectomy
Hb level and platelet count at each time point were
available for 30 patients in the non-Spx group. Although
Hb decline at 4 weeks after the initiation of PEG-IFN/
RBV tended to be greater in patients carrying the CC al-
lele than CA/AA allele (1.34 g/dl vs 0.96 g/dl, P = 0.09,
Figure 2A), there was no significant difference amongTable 2 Comparison of Data Among IL28B minor allele carrie
SVR group (n=4)
Age ≥60 (yes / no), n 1 / 3
Sex (male / female), n 2 / 2
Hemoglobin level (g/dl), mean ± SD 13.2 ± 0.8
Platelet count (x104/μl), mean ± SD 7.9 ± 0.9
Pretreatment viral load (logIU/mL), mean ± SD 6.5 ± 0.4
HCV genotype (1/2), n 3 / 1
splenectomy (yes / no), n 3 / 1
ITPA genotype (major/minor), n 3 / 1
CI; confidence interval, HCV; hepatitis C virus, IL28B; interleukin-28B, ITPA; inosine trthem. However, patients carrying the CC allele in the
non-Spx group were more susceptible to anemia than
those carrying the CA/AA allele (Hb decline of 1.74 g/dl
vs 0.60 g/dl, P < 0.05), whereas there was no difference
in Hb decline between patients carrying each genotype
in the Spx group (0.96 g/dl vs 1.28 g/dl, P = 0.89,
Figure 2B).
In addition, progression of anemia among patients car-
rying the CC allele was compared in each group
(Figure 2C). Before splenectomy, Hb level in patients in
the Spx group was lower than in the non-Spx group
(13.2 g/dl vs 12.3 g/dl, P < 0.05). In the Spx group, Hb
level did not change after splenectomy (12.3 g/dl vs 12.5
g/dl, P = 0.50) and was still lower than that in the non-
Spx group (13.2 g/dl vs 12.5 g/dl, P < 0.05). However,
Hb levels at 4 and 8 weeks after the initiation of
PEG-IFN/RBV were similar in each group (11.3 g/dl
vs 11.7 g/dl, P = 0.55, 10.8 g/dl vs 10.8 g/dl, P = 0.89,
respectively).ITPA genotype and platelet reduction during PEG-IFN/
RBV following splenectomy
Progression of thrombocytopenia in patients carrying
each ITPA genotype was compared in each group. There
was no difference in platelet count before PEG-IFN/RBV
between patients carrying the CC allele or CA/AA allele
(86.2 × 103/μl vs 86.9 × 103/μl, P = 0.86). Progression of
thrombocytopenia tended to be worse in patients carry-
ing the CA/AA allele, as reported previously, but there
was no significant difference in platelet count at 4, 8 and
12 weeks after initiation of PEG-IFN/RBV (69.9 × 103/μl
vs 63.2 × 103/μl; P = 0.26, 71.5 × 103/μl vs 61.3 × 103/μl;
P = 0.23, 69.5 × 103/μl vs 66.2 × 103/μl, P = 0.28, re-
spectively, Figure 3A).
Compared with pre- and postoperative platelet count,
although splenectomy improved thrombocytopenia in
whole splenectomy patients (61.1 × 103/μl vs 168.7 ×
103/μl, P < 0.01, data not shown), there was no differ-
ence in pre- or postoperative platelet count between
patients carrying the CC and CA/AA allele (60.4 × 103/rs who achieved SVR or not
Non-SVR group (n=35) Odds ratio P value 95% CI
23 / 12 0.17 n.s 0.01 – 1.85
19 / 16 0.84 n.s 0.11 – 6.67
12.9 ± 0.3 - n.s -
8.0 ± 0.3 - n.s -
6.3 ± 0.1 - n.s -
34 / 1 11.3 0.06 0.56 - 230
8 / 27 10.1 <0.05 0.92-112
26 / 9 1 n.s 0.09 – 11.2
iphosphate pyrophosphatase, n.s ; not significant, Spx; splenectomy.
Figure 2 ITPA genetic polymorphism and PEG-IFN/RBV-induced anemia. (A) ITPA genetic polymorphism and Hb decline at 4 weeks after
initiation of therapy among patients with HCV-induced cirrhosis. (B) ITPA genetic polymorphism and treatment-induced anemia in Spx and
non-Spx groups. (C) The changes of Hb levels among ITPA major carriers in the comparison of Spx and non-Spx groups.
Figure 3 ITPA genetic polymorphism and thrombocytopenia. (A) The progression of thrombocytopenia between CC and CA/AA allele
carriers in non-Spx group. (B) The progression of thrombocytopenia between CC and CA/AA allele carriers in Spx group. (C) The changes of
platelet count was compared between Spx and non-Spx groups.
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103/μl, P = 0.86, respectively). As shown in Figure 3B,
however, platelet counts in splenectomy patients carry-
ing the CA/AA allele tended to be lower than in those
carrying the CC allele at 4 and 8 weeks after initiation of
PEG-IFN/RBV (118.8 × 103/μl vs 91.6 × 103/μl; P = 0.12,
117.4 × 103/μl vs 89.3 × 103/μl, P = 0.14, respectively)
without any significant difference.
To clarify the efficacy of splenectomy in throm-
bocytopenia, platelet counts were compared between the
Spx and non-Spx groups at each time point (Figure 3C).
The patients in the non-Spx group were selected on
account of their platelet count <105/μl, but those
whose platelet count was <50–60 × 103/μl were sel-
dom induced with PEG-IFN/RBV, which led to a sig-
nificant difference in platelet count before splenectomy
(86.7 × 103/μl vs 58.9 × 103/μl, P < 0.01). However,
splenectomy increased the platelet count in the Spx
group to overtake that in the non-Spx group (86.7 ×
103/μl vs 164.3 × 103/μl, P < 0.01), and its dominance
was maintained even at 4 and 8 weeks after initiation
of PEG-IFN/RBV (67.7 × 103/μl vs 112.2 × 103/μl; P < .01,
68.1 × 103/μl vs 111.3 × 103/μl, P = 0.01, respectively).IL28B Genotype and splenic ISG expression
The correlation of IL28B and ITPA genetic variants with
the outcome of PEG-IFN/RBV therapy following splen-
ectomy was demonstrated. IL28B genetic variant has
also been reported to correlate with hepatic ISG expres-
sion among chronic hepatitis C patients [14]. Whether
IL28B genetic variant also correlated with splenic ISG
expression has yet to be determined. Surprisingly, asFigure 4 IL28B genetic polymorphism and splenic ISG expression. Bot
carrying the TT allele of IL28B.shown in Figure 4, both ISG15 and PKR expression in
the spleen was significantly higher in patients carrying
the TT allele than the TG/GG allele, which was opposite
to liver tissue as described previously (0.03 vs 0.02;
P < 0.05, 0.13 vs 0.10; P < 0.05, respectively).Discussion
Recent developments in genome sequence techniques
have enabled GWASs, which have resulted in tailored
therapies for various diseases. For patients affected with
HCV-related liver diseases, two important genetic poly-
morphisms, IL28B and ITPA, have been reported re-
cently, which hopefully will lead to appropriate antiviral
therapy for each individual.
Although splenectomy is useful for improving liver
function in type C cirrhotic patients for the induction of
PEG-IFN/RBV therapy, even less invasive laparoscopic
surgery carries some risks and has a high cost. The pre-
cise prediction for the outcome of PEG-IFN/RBV ther-
apy following LS is urgently needed.
The current study revealed that IL28B genetic variant
also correlated with response to PEG-IFN/RBV following
LS. Interestingly, compared to cirrhotic patients who
had not undergone splenectomy (non-Spx group) and
were carrying the TG/GG allele at the IL28B gene, those
who underwent splenectomy (Spx group) and carried
the TG/GG allele had a significantly higher SVR rate,
whereas TT carriers showed no difference between the
SPx and non-Spx groups.
One of the mechanisms by which splenectomy
improves antiviral response could be the restoration of
cytopenia, leading to enhanced treatment tolerance.h splenic ISG15 and PKR mRNA expression was higher in patients
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gene had greater susceptibility to anemia in the non-Spx
group, there was no difference between the ITPA geno-
types in the Spx group. Hitomi et al [15]. recently clari-
fied that ITPA genetic variant protected anemia by
accumulated inosine triphosphates been used for
decreased ATP via adnylosuccsinate synthase. In that
study, however, the authors reported that erythrocytes
with RBV in vitro did not show hemolysis by themselves,
suggesting that hemolysis occurred in other tissues
in vivo. In the current study, splenectomy did not
improved anemia, which was significantly worse than
that in the non-Spx group. Nevertheless, Hb levels dur-
ing the course of PEG-IFN/RBV therapy were similar in
the Spx and non-Spx groups among patients carrying
the CC allele. These data suggest that splenectomy does
not improve anemia, but protects against RBV-induced
hemolysis, especially among patients carrying the ITPA
CC allele.
In contrast to anemia, splenectomy itself significantly
improved thrombocytopenia, which enabled us to per-
form PEG-IFN/RBV therapy safely.
The restoration of peripheral blood cells does not ex-
plain why SVR was improved by splenectomy in patients
carrying the IL28B minor genotype. The current study
also revealed that splenic ISG expression was higher in
patients carrying the IL28B major genotype, which was
opposite to the liver. We consider that this resulted from
the difference in constituent cells in each organ. In fact,
the liver mainly comprises hepatocytes, whereas the
spleen mainly comprises monocytes. In a previous re-
port, IL28 mRNA expression was higher in peripheral
blood monocytes of patients carrying the TT allele than
those carrying the TG/GG allele [9]. ISG expression
was also reported to be higher in liver-infiltrating lym-
phocytes of responders to PEG-IFN/RBV than those of
non-responders [16]. Although it is unclear whether
monocytes have similar phenotypes in peripheral blood,
liver and spleen, pretreatment ISG expression was higher
in monocytes of patients carrying the IL28B major geno-
types. Similarly, Chen et al. have shown by immuno-
histochemistry that ISG15 protein upregulation was
pronounced in Kuppfer cells among responders to IFN
therapy [17]. Contrary to monocytes, ISGs from liver
parenchyma or hepatocytes are known to be greater in
number in non-responders to PEG-IFN/RBV [16,18].
These data suggest that pretreatment ISG upregulation
in hepatocytes in which HCV replicates induces refrac-
toriness to IFN, whereas monocytes that express little
endogenous ISG have some dysfunction for eradication
of HCV. Spleens in patients carrying the IL28B minor
genotype have some of these dysfunctional monocytes.
Therefore, it is possible that splenectomy removes such
monocytes and improves the outcome of PEG-IFN/RBVtherapy, especially in patients carrying the IL28B minor
genotype.
In addition, we have previously demonstrated that
the inhibitory signal, programmed-death 1(PD-1), is
upregulated in splenic CD4+ T cells and they promote
peripheral tolerance to IFN [19]. In fact, splenectomy
is followed by an increase in cytokine production and
a reduction of PD-1 in peripheral blood lymphocytes.
Not only PD-1, but also Tim-3, a well-known inhibi-
tory signal, are upregulated in HCV-specific T cells,
which are predominantly central memory T cells that
are located in lymphatic tissues such as the spleen
[20]. These data suggest that splenectomy does im-
prove the immune response to HCV, but confirmation
of the correlation of IL28B minor genotype with in-
hibitory signals in T cells needs further investigation.Conclusion
In conclusion, IL28B genetic polymorphism was also
correlated with response to PEG-IFN/RBV among cir-
rhotic patients following splenectomy and splenic ISG
expression. Splenectomy improved SVR rate, especially
among patients carrying the IL28B minor genotype, pro-
tecting against hemolytic anemia or thrombocytopenia,
regardless of ITPA genetic variants.
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